# Teva Pharmaceutical Industries Limited (TEVA) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $41.91, market value $48.9 billion.

## Valuation
- **P/E (trailing): 97.5×** (5-yr avg 23.4×, 3-yr avg 25.8×). Teva Pharmaceutical Industries Limited trades at 97.5× trailing earnings, well above its own five-year average of 23.4×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.07**. A PEG of 0.07 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.8×**. Each dollar of revenue is priced at 2.8×.
- **Price / book: 6.1×**. The shares trade at 6.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 18.2×**. Enterprise value is 18.2× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 2.8%** (5-yr avg 5.3%). Free cash flow equals 2.8% of the market value, below its five-year average of 5.3%, so the shares are pricier on cash than usual.
- **Earnings yield: 1.0%**. The inverse of the P/E: 1.0% of the price is earned each year.

## Profitability
- **Gross margin: 52.5%**. Teva Pharmaceutical Industries Limited keeps 52.5% of revenue after the direct cost of what it sells.
- **Operating margin: 9.3%**. 9.3% of revenue is left after running the business.
- **Net margin: 8.2%**. 8.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 17.8%**. 17.8% on shareholders' equity is solid.
- **Return on invested capital: 20.5%**. Return on all capital, debt included, is 20.5%: comfortably above what that capital costs.
- **Return on assets: 1.7%**. Each dollar of assets produces 1.7% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr 5.0%/yr, 5-yr 0.7%/yr). Revenue grew 4.3% over the last year, against 0.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 183.4%**. Earnings per share rose 183.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 3.3%/yr**. Free cash flow has compounded at 3.3% a year over three years.

## Financial health
- **Debt to equity: 0.23**. Debt is 0.23 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Teva Pharmaceutical Industries Limited holds more cash than debt.
- **Current ratio: 1.04** (quick 1.04). Current assets cover the next year's liabilities 1.04 times.
- **Altman Z-score: 1.78**. A Z-score of 1.78 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Teva Pharmaceutical Industries Limited does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Teva Pharmaceutical Industries Limited; the consensus is strong_buy, with an average price target of $47.58 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 98.7%** (YTD 30.4%, 3-mo 18.1%). The shares are up 98.7% over twelve months including dividends.
- **From 52-week high: -3.3%** (108.4% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.68** (volatility 39%). Beta of 0.68 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TEVA · Page: https://foliofundamentals.com/stocks/teva

Not investment advice.